Impact of methocarbamol on opioid use after primary ventral and inguinal hernia repair

Am J Surg. 2023 Dec;226(6):813-816. doi: 10.1016/j.amjsurg.2023.06.024. Epub 2023 Jun 22.

Abstract

Background: Multimodal analgesia is now a mainstay of perioperative care. Our aim is to assess the impact of adding methocarbamol on opioid use for patients undergoing primary ventral (umbilical and epigastric) hernia repair (PVHR) and inguinal hernia repair (IHR).

Methods: Retrospective review of patients undergoing PVHR and IHR who received methocarbamol, propensity score matched in a 2:1 fashion to patients not receiving methocarbamol.

Results: Fifty-two PVHR patients receiving methocarbamol were matched to 104 control patients. Study patients were prescribed fewer opioids (55.8 vs 90.4%; p < 0.001) and received lower MME (20 vs 50; p < 0.001), with no difference in refills or rescue opioids. For IHR, study patients received fewer prescriptions (67.3 vs 87.5%; p < 0.001) and received lower MME (25 vs 40; p < 0.001), with no difference in rescue opioid (5.9 vs 0%; p = 0.374).

Conclusions: Methocarbamol significantly reduced opioid prescribing in patients undergoing PVHR and IHR without increasing the risk of refill or rescue opioid.

Keywords: Inguinal hernia repair; Methocarbamol; Multimodal pain; Opioid; Primary ventral hernia repair.

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Hernia, Inguinal* / surgery
  • Herniorrhaphy
  • Humans
  • Methocarbamol* / therapeutic use
  • Opioid-Related Disorders* / prevention & control
  • Pain, Postoperative / drug therapy
  • Pain, Postoperative / surgery
  • Practice Patterns, Physicians'
  • Retrospective Studies

Substances

  • Analgesics, Opioid
  • Methocarbamol
  • MME